396 related articles for article (PubMed ID: 28114767)
1. Artificial Virus Delivers CRISPR-Cas9 System for Genome Editing of Cells in Mice.
Li L; Song L; Liu X; Yang X; Li X; He T; Wang N; Yang S; Yu C; Yin T; Wen Y; He Z; Wei X; Su W; Wu Q; Yao S; Gong C; Wei Y
ACS Nano; 2017 Jan; 11(1):95-111. PubMed ID: 28114767
[TBL] [Abstract][Full Text] [Related]
2. Sono-Controllable and ROS-Sensitive CRISPR-Cas9 Genome Editing for Augmented/Synergistic Ultrasound Tumor Nanotherapy.
Pu Y; Yin H; Dong C; Xiang H; Wu W; Zhou B; Du D; Chen Y; Xu H
Adv Mater; 2021 Nov; 33(45):e2104641. PubMed ID: 34536041
[TBL] [Abstract][Full Text] [Related]
3. A multifunctional non-viral vector for the delivery of MTH1-targeted CRISPR/Cas9 system for non-small cell lung cancer therapy.
Wang Y; Tang Y; Zhao XM; Huang G; Gong JH; Yang SD; Li H; Wan WJ; Jia CH; Chen G; Zhang XN
Acta Biomater; 2022 Nov; 153():481-493. PubMed ID: 36162766
[TBL] [Abstract][Full Text] [Related]
4. Scaffold-mediated non-viral delivery platform for CRISPR/Cas9-based genome editing.
Chin JS; Chooi WH; Wang H; Ong W; Leong KW; Chew SY
Acta Biomater; 2019 May; 90():60-70. PubMed ID: 30978509
[TBL] [Abstract][Full Text] [Related]
5. A Rationally Designed Semiconducting Polymer Brush for NIR-II Imaging-Guided Light-Triggered Remote Control of CRISPR/Cas9 Genome Editing.
Li L; Yang Z; Zhu S; He L; Fan W; Tang W; Zou J; Shen Z; Zhang M; Tang L; Dai Y; Niu G; Hu S; Chen X
Adv Mater; 2019 May; 31(21):e1901187. PubMed ID: 30957918
[TBL] [Abstract][Full Text] [Related]
6. Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications.
Liu C; Zhang L; Liu H; Cheng K
J Control Release; 2017 Nov; 266():17-26. PubMed ID: 28911805
[TBL] [Abstract][Full Text] [Related]
7. Cancer-derived exosomes as a delivery platform of CRISPR/Cas9 confer cancer cell tropism-dependent targeting.
Kim SM; Yang Y; Oh SJ; Hong Y; Seo M; Jang M
J Control Release; 2017 Nov; 266():8-16. PubMed ID: 28916446
[TBL] [Abstract][Full Text] [Related]
8. A Photolabile Semiconducting Polymer Nanotransducer for Near-Infrared Regulation of CRISPR/Cas9 Gene Editing.
Lyu Y; He S; Li J; Jiang Y; Sun H; Miao Y; Pu K
Angew Chem Int Ed Engl; 2019 Dec; 58(50):18197-18201. PubMed ID: 31566854
[TBL] [Abstract][Full Text] [Related]
9. Methods for In Vivo CRISPR/Cas Editing of the Adult Murine Retina.
Hung SS; Li F; Wang JH; King AE; Bui BV; Liu GS; Hewitt AW
Methods Mol Biol; 2018; 1715():113-133. PubMed ID: 29188510
[TBL] [Abstract][Full Text] [Related]
10. Development of a CRISPR/Cas9 genome editing toolbox for Corynebacterium glutamicum.
Liu J; Wang Y; Lu Y; Zheng P; Sun J; Ma Y
Microb Cell Fact; 2017 Nov; 16(1):205. PubMed ID: 29145843
[TBL] [Abstract][Full Text] [Related]
11. Genome Editing in a Wide Area of the Brain Using Dendrimer-Based Ternary Polyplexes of Cas9 Ribonucleoprotein.
Taharabaru T; Yokoyama R; Higashi T; Mohammed AFA; Inoue M; Maeda Y; Niidome T; Onodera R; Motoyama K
ACS Appl Mater Interfaces; 2020 May; 12(19):21386-21397. PubMed ID: 32315156
[TBL] [Abstract][Full Text] [Related]
12. CRISPR-Cas9 Delivery by Artificial Virus (RRPHC).
Yang S; Wu Q; Wei Y; Gong C
Methods Mol Biol; 2019; 1961():81-91. PubMed ID: 30912041
[TBL] [Abstract][Full Text] [Related]
13. Cationic Polymer-Mediated CRISPR/Cas9 Plasmid Delivery for Genome Editing.
Zhang Z; Wan T; Chen Y; Chen Y; Sun H; Cao T; Songyang Z; Tang G; Wu C; Ping Y; Xu FJ; Huang J
Macromol Rapid Commun; 2019 Mar; 40(5):e1800068. PubMed ID: 29708298
[TBL] [Abstract][Full Text] [Related]
14. Multifunctional Vector for Delivery of Genome Editing Plasmid Targeting β-Catenin to Remodulate Cancer Cell Properties.
He XY; Liu BY; Peng Y; Zhuo RX; Cheng SX
ACS Appl Mater Interfaces; 2019 Jan; 11(1):226-237. PubMed ID: 30540162
[TBL] [Abstract][Full Text] [Related]
15. Enhanced Cytosolic Delivery and Release of CRISPR/Cas9 by Black Phosphorus Nanosheets for Genome Editing.
Zhou W; Cui H; Ying L; Yu XF
Angew Chem Int Ed Engl; 2018 Aug; 57(32):10268-10272. PubMed ID: 29939484
[TBL] [Abstract][Full Text] [Related]
16. CRISPR/Cas9-Based Antiviral Strategy: Current Status and the Potential Challenge.
Lee C
Molecules; 2019 Apr; 24(7):. PubMed ID: 30959782
[TBL] [Abstract][Full Text] [Related]
17. Co-delivery of Sorafenib and CRISPR/Cas9 Based on Targeted Core-Shell Hollow Mesoporous Organosilica Nanoparticles for Synergistic HCC Therapy.
Zhang BC; Luo BY; Zou JJ; Wu PY; Jiang JL; Le JQ; Zhao RR; Chen L; Shao JW
ACS Appl Mater Interfaces; 2020 Dec; 12(51):57362-57372. PubMed ID: 33301289
[TBL] [Abstract][Full Text] [Related]
18. Gene editing of MPS I human fibroblasts by co-delivery of a CRISPR/Cas9 plasmid and a donor oligonucleotide using nanoemulsions as nonviral carriers.
Schuh RS; de Carvalho TG; Giugliani R; Matte U; Baldo G; Teixeira HF
Eur J Pharm Biopharm; 2018 Jan; 122():158-166. PubMed ID: 29122734
[TBL] [Abstract][Full Text] [Related]
19. Development of a genome editing technique using the CRISPR/Cas9 system in the industrial filamentous fungus Aspergillus oryzae.
Katayama T; Tanaka Y; Okabe T; Nakamura H; Fujii W; Kitamoto K; Maruyama J
Biotechnol Lett; 2016 Apr; 38(4):637-42. PubMed ID: 26687199
[TBL] [Abstract][Full Text] [Related]
20. Baculoviral delivery of CRISPR/Cas9 facilitates efficient genome editing in human cells.
Hindriksen S; Bramer AJ; Truong MA; Vromans MJM; Post JB; Verlaan-Klink I; Snippert HJ; Lens SMA; Hadders MA
PLoS One; 2017; 12(6):e0179514. PubMed ID: 28640891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
